Tong Ren Tang Technologies Co. Ltd.

SEHK:1666 Stock Report

Mkt Cap: HK$7.6b

We’ve recently updated our valuation analysis.

Tong Ren Tang Technologies Valuation

Is 1666 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1666?

Other financial metrics that can be useful for relative valuation.

1666 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA5x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does 1666's PE Ratio compare to its peers?

The above table shows the PE ratio for 1666 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.1x
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
24.3xn/aHK$8.6b
3933 United Laboratories International Holdings
8x0.2%HK$9.2b
6600 SciClone Pharmaceuticals (Holdings)
7.4x-1.3%HK$7.1b
2877 China Shineway Pharmaceutical Group
8.6x9.4%HK$5.8b
1666 Tong Ren Tang Technologies
12.9x5.7%HK$7.6b

Price-To-Earnings vs Peers: 1666 is expensive based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (12.1x).


Price to Earnings Ratio vs Industry

How does 1666's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.8%
n/an/an/a

Price-To-Earnings vs Industry: 1666 is expensive based on its Price-To-Earnings Ratio (12.9x) compared to the Hong Kong Pharmaceuticals industry average (10.7x)


Price to Earnings Ratio vs Fair Ratio

What is 1666's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1666 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.9x
Fair PE Ratio12x

Price-To-Earnings vs Fair Ratio: 1666 is expensive based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (12x).


Share Price vs Fair Value

What is the Fair Price of 1666 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1666 (HK$5.93) is trading below our estimate of fair value (HK$16.08)

Significantly Below Fair Value: 1666 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1666 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$5.93
HK$7.12
+20.1%
1.7%HK$7.24HK$7.00n/a2
Jan ’24HK$5.65
HK$7.12
+26.0%
1.7%HK$7.24HK$7.00n/a2
Dec ’23HK$5.28
HK$7.12
+34.9%
1.7%HK$7.24HK$7.00n/a2
Nov ’23HK$4.15
HK$7.12
+71.6%
1.7%HK$7.24HK$7.00n/a2
Oct ’23HK$4.58
HK$7.24
+58.0%
4.8%HK$7.58HK$6.89n/a2
Sep ’23HK$5.42
HK$7.24
+33.5%
4.8%HK$7.58HK$6.89n/a2
Aug ’23HK$5.35
HK$7.69
+43.7%
8.9%HK$8.37HK$7.00n/a2
Jul ’23HK$6.59
HK$8.03
+21.8%
10.3%HK$8.85HK$7.20n/a2
Jun ’23HK$5.91
HK$8.03
+35.8%
10.3%HK$8.85HK$7.20n/a2
May ’23HK$6.04
HK$8.03
+32.9%
10.3%HK$8.85HK$7.20n/a2
Apr ’23HK$6.55
HK$8.03
+22.5%
10.3%HK$8.85HK$7.20n/a2
Mar ’23HK$6.72
HK$7.09
+5.5%
2.7%HK$7.28HK$6.90n/a2
Feb ’23HK$7.29
HK$7.05
-3.3%
2.2%HK$7.20HK$6.90n/a2
Jan ’23HK$8.38
HK$7.05
-15.9%
2.2%HK$7.20HK$6.90HK$5.652
Dec ’22HK$6.03
HK$7.05
+16.9%
2.2%HK$7.20HK$6.90HK$5.282
Nov ’22HK$5.54
HK$7.05
+27.3%
2.2%HK$7.20HK$6.90HK$4.152
Oct ’22HK$5.84
HK$7.25
+24.1%
2.1%HK$7.40HK$7.09HK$4.582
Sep ’22HK$6.01
HK$7.25
+20.6%
2.1%HK$7.40HK$7.09HK$5.422
Aug ’22HK$5.73
HK$7.06
+23.2%
0.9%HK$7.12HK$7.00HK$5.352
Jul ’22HK$7.13
HK$7.06
-1.0%
0.9%HK$7.12HK$7.00HK$6.592
Jun ’22HK$7.75
HK$7.06
-8.9%
0.9%HK$7.12HK$7.00HK$5.912
May ’22HK$6.16
HK$7.06
+14.6%
0.9%HK$7.12HK$7.00HK$6.042
Apr ’22HK$5.39
HK$6.77
+25.6%
4.8%HK$7.10HK$6.45HK$6.552
Mar ’22HK$5.35
HK$7.11
+32.9%
7.3%HK$7.50HK$6.37HK$6.723
Feb ’22HK$4.94
HK$7.11
+43.9%
7.3%HK$7.50HK$6.37HK$7.293
Jan ’22HK$4.85
HK$7.11
+46.6%
7.3%HK$7.50HK$6.37HK$8.383

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies